Choosing the right inhaler to deliver treatment for people with chronic obstructive pulmonary disease (COPD) may require considering their cognitive function, hand dexterity, and ability to breathe in forcefully, according to data from a large observational study in the U.S. Researchers found that nearly three in every 10 participants…
News
When levels of black carbon, or soot, in the air are high, walking outside can worsen cough and increase mucus production in people with chronic obstructive pulmonary disease (COPD), a new study shows. The researchers note that their findings do not change existing recommendations that people with COPD should…
AERO-007 — a combination of two classes of bronchodilators delivered via a standard jet nebulizer — led to rapid and clinically meaningful improvements in lung function among adults with moderate-to-severe chronic obstructive pulmonary disease (COPD). That’s according to data from the Phase 2a portion of a Phase 1/2a…
One year of treatment with tozorakimab, AstraZeneca’s experimental therapy, was reported to significantly reduce the annual rate of moderate-to-severe exacerbations, or periods of sudden symptom worsening, in adults with chronic obstructive pulmonary disease (COPD). These are the top-line results from the global Phase 3 MIRANDA clinical trial (NCT06040086),…
The experimental therapy tozorakimab from AstraZeneca was superior to a placebo at reducing the rate of moderate to severe exacerbations, or sudden episodes of symptom worsening, in adults with chronic obstructive pulmonary disease (COPD). That’s according to top-line, one-year data from two Phase 3 clinical trials —…
For people with chronic obstructive pulmonary disease (COPD), characterized by cough and shortness of breath, Anoro Elipta (umeclidinium-vilanterol) may work better than other approved COPD medications at reducing the risk of disease flares. That’s according to a new federally funded study that used U.S. insurance data to compare…
A novel test based on the levels and composition of certain proteins in mucus, called mucins, may help assess lung health in people with chronic obstructive pulmonary disease (COPD), according to a new study. Findings show that higher Mucin Quantitative Score (MUCQ) values were significantly associated with worse lung…
The first person with chronic obstructive pulmonary disease (COPD) has now been dosed with BBT002, an experimental medication being developed by Bambusa Therapeutics, in an ongoing Phase 1b clinical trial. The trial (NCT06944925) is evaluating BBT002’s safety and pharmacological properties against a placebo in up to 98…
Mabwell’s experimental therapy 9MW1911 may reduce the frequency of moderate to severe exacerbations in people with chronic obstructive pulmonary disease (COPD), according to data from a completed Phase 2a clinical trial. The results were announced in a press release from Mabwell. The company is now conducting a…
The American Lung Association Research Institute is investing $22 million to advance research and support care for lung disease, including chronic obstructive pulmonary disease (COPD). “Research is the foundation for every breakthrough that improves lung health and saves lives,” said Harold Wimmer, president and CEO of the…
Recent Posts
- Study links cognitive function, hand dexterity to proper inhaler use in COPD
- In life with COPD, I’m blessed with a good and faithful friend
- I’m learning a new vocabulary that grants me the courage to face each day
- Like the lightning bug, I flash my lantern against the darkness
- The supplements and mountain wisdom that help me manage my COPD